Page 6 - Executive Albert Bourla News Today

(Adds details on vaccine doses, background; updates share movement) May 4 (Reuters) - Pfizer Inc on Tuesday forecast $26 billion in COVID-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination. The raised goal assumes 1.6 billion doses of vaccine, which is co-developed with BioNTech SE, will be delivered in the year, with the two-shot vaccine emerging as the best-...

The drugmaker and its German partner on the vaccine, BioNTech, continue to sign contracts with multiple countries for their two-dose shot. They reported $3.46 billion in first-quarter sales and now expect to rake in roughly $26 billion over the year, up from their prior forecast of about $15 billion.

Pfizer, buoyed by a huge jump in sales for its COVID-19 vaccine and solid performance across most of the company, is hiking its 2021 financial forecast sharply after blowing past Wall Street expectations for the first quarter.  The New York drugmaker and its German partner on the vaccine, BioNTech, continue to sign contracts with multiple countries for their two-dose shot. They reported $3.46 billion in first-quarter sales and now expect to rake in roughly $26 billion over the year, up from th...

Pfizer is raising its 2021 revenue expectations amid the successful rollout of its COVID-19 vaccine and strong performances from many  other medicines

 04 May 2021 - 17:17 The Pfizer logo is pictured at their building in the Manhattan borough of New York October 29, 2015. REUTERS/Carlo Allegri/File Photo Reuters Pfizer Inc on Tuesday raised its forecast for 2021 COVID-19 vaccine sales by more than 70% to $26 billion and said demand from governments around the world trying to halt the pandemic could contribute to its growth for years to come. Revenue from the vaccine - developed with German partner BioNTech SE - is expected to account for mo...

Pfizer Inc on Tuesday forecast $26 billion in COVID-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination. The raised goal assumes 1.6 billion doses of vaccine, which is co-developed with BioNTech SE, will be delivered in the year, with the two-shot vaccine emerging as the best-selling product for the U.S. drugmaker in the first quarter. It is expected to make ...

Published May 4, 2021 10:00pm Pfizer sharply increased its projections for 2021 revenues and profits on Tuesday, citing much higher COVID-19 vaccine sales as it targets the inoculations as a "durable" revenue stream. The drugmaker, which has a number of projects to expand vaccinations to additional populations and to provide booster doses, now estimates 2021 revenues of $26 billion from the vaccine, up from $15 billion previously. Pfizer now sees profits of between $3.55 and $3.65 a share ...